Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, April 04, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it intends to commence an underwritten public offering of its ordinary shares. Jefferies LLC is acting as sole book-running manager and BTIG, LLC
View HTML
Toggle Summary Quotient Reports Continued Positive MosaiQ™ Performance Evaluation Results
Antibody Detection — enhanced detection versus predicate technologies Manufacturing of Microarrays for European field trials planned to commence in early April MosaiQ ™ instrument development completed and formal validation has commenced Completion of European field trials expected in
View HTML
Toggle Summary FDA Licenses Eight New Quotient Reagent Products for Sale in the U.S.
Products are rare antisera blood typing reagents developed and manufactured by Quotient U.S. commercialization of these products will extend the range and method of reagents available in the market for antigen phenotyping Equivalent products are already approved and commercialized outside of the
View HTML
Toggle Summary Quotient Limited to Participate in the Cowen and Company 37th Annual Health Care Conference
JERSEY, Channel Islands, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Cowen and Company 37 th Annual Health Care Conference on
View HTML
Toggle Summary Quotient Limited Announces Appointment of Christopher Lindop as Chief Financial Officer
JERSEY, Channel Islands, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Christopher Lindop as Chief Financial Officer.  Mr. Lindop will commence his new role on February 15, 2017. Mr.
View HTML
Toggle Summary Quotient Limited Reports Continued Progress on the Commercial Scale-up of MosaiQ™ and Third Quarter Fiscal 2017 Financial Results
Performance evaluation studies for initial disease screening panel completed successfully Completion of European field trials expected in first half of 2017 Conventional reagent business continues strong performance JERSEY, Channel Islands, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Quotient Limited
View HTML
Toggle Summary Quotient Limited to Report Third Quarter Fiscal 2017 Financial Results and Host Conference Call
JERSEY, Channel Islands, Jan. 24, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2016 will be released after market close on Monday, February 6, 2017.
View HTML
Toggle Summary Quotient Limited Reports Positive MosaiQ™ Results From Performance Evaluation Study for Blood Grouping
Root-cause investigation completed and corrective actions implemented Performance evaluation study for antigen typing achieves targeted endpoints Completion of European field trials expected in the first half of 2017 JERSEY, Channel Islands, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Quotient Limited
View HTML
Toggle Summary Quotient Limited to Participate in the 35th Annual J.P. Morgan Healthcare Conference
JERSEY, Channel Islands, Dec. 21, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the company's Chairman and Chief Executive Officer, Paul Cowan, will present at the 35 th annual J.P.
View HTML
Toggle Summary Quotient Limited to Participate in the 2016 Evercore ISI MedTools Conference
JERSEY, Channel Islands, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's senior management team, including Chairman and Chief Executive Officer, Paul Cowan, will participate in the Evercore ISI MedTools
View HTML